174 related articles for article (PubMed ID: 17108039)
1. Inhibition of heavy chain and beta2-microglobulin synthesis as a mechanism of major histocompatibility complex class I downregulation during Epstein-Barr virus replication.
Guerreiro-Cacais AO; Uzunel M; Levitskaya J; Levitsky V
J Virol; 2007 Feb; 81(3):1390-400. PubMed ID: 17108039
[TBL] [Abstract][Full Text] [Related]
2. The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.
Quinn LL; Williams LR; White C; Forrest C; Zuo J; Rowe M
J Virol; 2016 Jan; 90(1):356-67. PubMed ID: 26468525
[TBL] [Abstract][Full Text] [Related]
3. The lytic cycle of Epstein-Barr virus is associated with decreased expression of cell surface major histocompatibility complex class I and class II molecules.
Keating S; Prince S; Jones M; Rowe M
J Virol; 2002 Aug; 76(16):8179-88. PubMed ID: 12134023
[TBL] [Abstract][Full Text] [Related]
4. Major histocompatibility complex (MHC)-I and MHC-II expression in Hodgkin's disease in relation to the presence of Epstein-Barr Virus (EBV).
Tzardi M; Kouvidou C; Papakonstantinou E; Datseris G; Darivianaki K; Karidi E; Eliopoulos G; Delidis G; Rontogianni D; Kanavaros P
Anticancer Res; 1996; 16(2):827-31. PubMed ID: 8687136
[TBL] [Abstract][Full Text] [Related]
5. Expression and characterization of recombinant single-chain salmon class I MHC fused with beta2-microglobulin with biological activity.
Zhao H; Stet RJ; Skjødt K; Savelkoul HF
Fish Shellfish Immunol; 2008 Apr; 24(4):459-66. PubMed ID: 18280180
[TBL] [Abstract][Full Text] [Related]
6. Down-regulation of locus-specific human lymphocyte antigen class I expression in Epstein-Barr virus-associated gastric cancer: implication for viral-induced immune evasion.
Dutta N; Gupta A; Mazumder DN; Banerjee S
Cancer; 2006 Apr; 106(8):1685-93. PubMed ID: 16541432
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of MHC class II expression through inhibition of CIITA transcription by lytic transactivator Zta during Epstein-Barr virus reactivation.
Li D; Qian L; Chen C; Shi M; Yu M; Hu M; Song L; Shen B; Guo N
J Immunol; 2009 Feb; 182(4):1799-809. PubMed ID: 19201831
[TBL] [Abstract][Full Text] [Related]
8. Stage-specific inhibition of MHC class I presentation by the Epstein-Barr virus BNLF2a protein during virus lytic cycle.
Croft NP; Shannon-Lowe C; Bell AI; Horst D; Kremmer E; Ressing ME; Wiertz EJ; Middeldorp JM; Rowe M; Rickinson AB; Hislop AD
PLoS Pathog; 2009 Jun; 5(6):e1000490. PubMed ID: 19557156
[TBL] [Abstract][Full Text] [Related]
9. Epstein-Barr virus infection of CR2-transfected epithelial cells reveals the presence of MHC class II on the virion.
Knox PG; Young LS
Virology; 1995 Oct; 213(1):147-57. PubMed ID: 7483258
[TBL] [Abstract][Full Text] [Related]
10. Biosynthesis of HLA-C heavy chains in melanoma cells with multiple defects in the expression of HLA-A, -B, -C molecules.
Martayan A; Fraioli R; Giorda E; Setini A; Ciccarelli G; Delfino L; Ferrara GB; Giacomini P
Br J Cancer; 1999 May; 80(5-6):639-49. PubMed ID: 10360639
[TBL] [Abstract][Full Text] [Related]
11. Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: beta2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors.
Cabrera CM; Jiménez P; Cabrera T; Esparza C; Ruiz-Cabello F; Garrido F
Tissue Antigens; 2003 Mar; 61(3):211-9. PubMed ID: 12694570
[TBL] [Abstract][Full Text] [Related]
12. Assembly and retention of CD1b heavy chains in the endoplasmic reticulum.
Sugita M; Porcelli SA; Brenner MB
J Immunol; 1997 Sep; 159(5):2358-65. PubMed ID: 9278326
[TBL] [Abstract][Full Text] [Related]
13. Kinetics and thermodynamics of beta 2-microglobulin binding to the alpha 3 domain of major histocompatibility complex class I heavy chain.
Hebert AM; Strohmaier J; Whitman MC; Chen T; Gubina E; Hill DM; Lewis MS; Kozlowski S
Biochemistry; 2001 May; 40(17):5233-42. PubMed ID: 11318646
[TBL] [Abstract][Full Text] [Related]
14. Reduced expression of major histocompatibility complex class I free heavy chains and enhanced sensitivity to natural killer cells after incubation of human lymphoid lines with beta 2-microglobulin.
Carbone E; Stuber G; Andrée S; Franksson L; Klein E; Beretta A; Siccardi AG; Kärre K
Eur J Immunol; 1993 Aug; 23(8):1752-6. PubMed ID: 7688306
[TBL] [Abstract][Full Text] [Related]
15. Modified human beta 2-microglobulin (desLys(58)) displays decreased affinity for the heavy chain of MHC class I and induces nitric oxide production and apoptosis.
Wang M; Harhaji L; Lamberth K; Harndahl M; Buus S; Heegaard NH; Claesson MH; Nissen MH
Scand J Immunol; 2009 Mar; 69(3):203-12. PubMed ID: 19281532
[TBL] [Abstract][Full Text] [Related]
16. Induction of rainbow trout MH class I and accessory proteins by viral haemorrhagic septicaemia virus.
Sever L; Vo NT; Lumsden J; Bols NC; Dixon B
Mol Immunol; 2014 Jun; 59(2):154-62. PubMed ID: 24607971
[TBL] [Abstract][Full Text] [Related]
17. Invariant chain association with MHC class I: preference for HLA class I/beta 2-microglobulin heterodimers, specificity, and influence of the MHC peptide-binding groove.
Vigna JL; Smith KD; Lutz CT
J Immunol; 1996 Nov; 157(10):4503-10. PubMed ID: 8906828
[TBL] [Abstract][Full Text] [Related]
18. Distinct patterns of folding and interactions with calnexin and calreticulin in human class I MHC proteins with altered N-glycosylation.
Zhang Q; Salter RD
J Immunol; 1998 Jan; 160(2):831-7. PubMed ID: 9551918
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the interactions between MHC class I subunits: a systematic approach for the engineering of higher affinity variants of beta 2-microglobulin.
Shields MJ; Assefi N; Hodgson W; Kim EJ; Ribaudo RK
J Immunol; 1998 Mar; 160(5):2297-307. PubMed ID: 9498770
[TBL] [Abstract][Full Text] [Related]
20. The β2-microglobulin-free heterodimerization of rhesus monkey MHC class I A with its normally spliced variant reduces the ubiquitin-dependent degradation of MHC class I A.
Dai ZX; Zhang GH; Zhang XH; Xia HJ; Li SY; Zheng YT
J Immunol; 2012 Mar; 188(5):2285-96. PubMed ID: 22291188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
